| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 6199 | 2020 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2682 | 2020 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1856 | 2021 |
| Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study app CH Sudre, KA Lee, M Ni Lochlainn, T Varsavsky, B Murray, MS Graham, ... Science advances 7 (12), eabd4177, 2021 | 214 | 2021 |
| Clinician experiences with screening for social needs in primary care ST Tong, WR Liaw, PL Kashiri, J Pecsok, J Rozman, AW Bazemore, ... The Journal of the American Board of Family Medicine 31 (3), 351-363, 2018 | 152 | 2018 |
| Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, ... The Lancet Respiratory Medicine 9 (12), 1365-1376, 2021 | 151 | 2021 |
| Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, ... The lancet respiratory medicine 10 (9), 888-899, 2022 | 96 | 2022 |
| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... Science Translational Medicine 14 (645), eabn8543, 2022 | 86 | 2022 |
| Remdesivir for the treatment of Covid-19-preliminary report JH McMahon, A Udy, AY Peleg The New England journal of medicine 383 (10), 992-993, 2020 | 84 | 2020 |
| Gaps in well-child care attendance among primary care clinics serving low-income families ER Wolf, CJ Hochheimer, RT Sabo, J DeVoe, R Wasserman, E Geissal, ... Pediatrics 142 (5), 2018 | 78 | 2018 |
| Chronic opioid prescribing in primary care: factors and perspectives ST Tong, CJ Hochheimer, EM Brooks, RT Sabo, V Jiang, T Day, ... The Annals of Family Medicine 17 (3), 200-206, 2019 | 67 | 2019 |
| Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection SA Richard, SD Pollett, AC Fries, CM Berjohn, RC Maves, T Lalani, ... JAMA network open 6 (1), e2251360-e2251360, 2023 | 50 | 2023 |
| Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history W Wang, S Lusvarghi, R Subramanian, NJ Epsi, R Wang, E Goguet, ... Cell host & microbe 30 (12), 1745-1758. e7, 2022 | 44 | 2022 |
| Durability of SARS-CoV-2–specific T-cell responses at 12 months postinfection Z Lu, ED Laing, J Pena DaMata, K Pohida, MS Tso, EC Samuels, NJ Epsi, ... The Journal of Infectious Diseases 224 (12), 2010-2019, 2021 | 38 | 2021 |
| Caregiver and clinician perspectives on missed well-child visits ER Wolf, J O’Neil, J Pecsok, RS Etz, DJ Opel, R Wasserman, AH Krist The Annals of Family Medicine 18 (1), 30-34, 2020 | 37 | 2020 |
| AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019 M Levin, A Ustianowski, S Thomas, A Templeton, Y Yuan, S Seegobin, ... Clinical Infectious Diseases, 2022 | 33 | 2022 |
| Understanding “hybrid immunity”: comparison and predictors of humoral immune responses to severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) and coronavirus … NJ Epsi, SA Richard, DA Lindholm, K Mende, A Ganesan, N Huprikar, ... Clinical Infectious Diseases 76 (3), e439-e449, 2023 | 25 | 2023 |
| COVID-19 outcomes among US Military Health System beneficiaries include complications across multiple organ systems and substantial functional impairment SA Richard, SD Pollett, CA Lanteri, EV Millar, AC Fries, RC Maves, ... Open Forum Infectious Diseases 8 (12), ofab556, 2021 | 24 | 2021 |
| SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity ED Laing, NJ Epsi, SA Richard, EC Samuels, W Wang, R Vassell, ... medrxiv, 2021.04. 27.21256207, 2021 | 24 | 2021 |
| Understanding ‘hybrid immunity’: comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines NJ Epsi, SA Richard, DA Lindholm, K Mende, A Ganesan, N Huprikar, ... Clin Infect Dis 76 (3), e439-49, 2022 | 23 | 2022 |